Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01273636
Other study ID # 200712018R
Secondary ID
Status Recruiting
Phase N/A
First received August 14, 2008
Last updated January 6, 2011
Start date January 2005
Est. completion date June 2011

Study information

Verified date December 2010
Source National Taiwan University Hospital
Contact Chi-An Chen, Professor
Phone 886-2-23123456
Email chianchen@ntu.edu.tw
Is FDA regulated No
Health authority Taiwan: Department of Health
Study type Observational

Clinical Trial Summary

Objective: To examine the risk factors for coexisting endometrial carcinoma in patients with endometrial hyperplasia.

Method: Seventy-seven patients who received hysterectomy for endometrial hyperplasia were enrolled and divided into the non-endometrial carcinoma group (57) and the endometrial carcinoma group (20) depending on the final pathology. Clinical variables were analyzed.


Description:

We retrospectively reviewed the cases of seventy-seven patients who had hysterectomies for endometrial hyperplasia between January 1996 and September 2006 at the Department of Obstetrics and Gynecology, National Taiwan University Hospital. A preoperative pathologic diagnosis of endometrial hyperplasia was obtained by D&C (dilation and curettage) in all patients. Twenty of them were diagnosed as having endometrial carcinoma in their hysterectomy specimens. All of the specimens were reviewed by a gynecologic pathologist.

Depending on the final pathologic reports of hysterectomy, we divided the seventy-seven patients into two groups - the non-endometrial carcinoma group and the endometrial carcinoma group. Fifty-seven of the studied patients were in the non-endometrial carcinoma group and twenty were in the endometrial carcinoma group. As already mentioned above, we investigated them by clinical parameters including age, menopausal status, obstetrical history, medical history of diabetes and hypertension, BMI (body mass index) and preoperative pathology of D&C.

The clinical and pathologic characteristics of the twenty patients diagnosed as having endometrial carcinoma postoperatively were also reviewed. Initial manifestation, histological grading of the carcinoma, the depth of myometrial invasion, with or without adjuvant radiotherapy and recurrence were included. The histological grading of endometrial carcinoma was based on FIGO ( International Federation of Gynecology and Obstetrics ) definitions. The BMIs of the patients with endometrial carcinoma were also analyzed by the receiver operating characteristic curve. The Research and Ethics Committee of National Taiwan University Hospital approved this study.

Statistical analyses were performed with the Independent-Samples T test and the Mann-Whitney test. Subsequently, multivariate analysis of risk factors was also employed with Binary logistic regression model to obtain the adjusted odds ratio (OR) and 95% confidence interval (CI) for selective variables. P<0.05 was defined as significant.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date June 2011
Est. primary completion date January 2006
Accepts healthy volunteers No
Gender Female
Age group 30 Years to 70 Years
Eligibility Inclusion Criteria:

- Endometrial hyperplasia patient having hysterectomy with or without bilateral salpingo-oophorectomy

Exclusion Criteria:

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective


Locations

Country Name City State
Taiwan Chi-An Chen Taipei
Taiwan Chi-An Chen Taipei

Sponsors (1)

Lead Sponsor Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary The prognosis of patients diagnosed as endometrial carcinoma after hysterectomy. From carcinoma diagnosed to the last patient follow-up or death till June, 2011 No
See also
  Status Clinical Trial Phase
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Recruiting NCT05036681 - A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma Phase 2
Completed NCT00756847 - Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors Phase 1
Completed NCT00729586 - Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer Phase 2
Completed NCT02983279 - Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer N/A
Completed NCT02017353 - Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma Phase 2
Completed NCT00997373 - Letrozole as a Treatment of Endometrial Cancer N/A
Recruiting NCT04851119 - Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Phase 1/Phase 2
Recruiting NCT04576104 - Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer Phase 2
Not yet recruiting NCT06102252 - Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as an Adjuvant Treatment in Endometrial Carcinoma N/A
Active, not recruiting NCT02598219 - Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence. Phase 3
Recruiting NCT04159155 - A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer Phase 2/Phase 3
Recruiting NCT05139368 - Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer N/A
Recruiting NCT02611024 - Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors Phase 1/Phase 2
Completed NCT03849469 - A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors Phase 1
Suspended NCT06253494 - Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer Phase 1/Phase 2
Active, not recruiting NCT03917381 - GEN1046 Safety Trial in Patients With Malignant Solid Tumors Phase 1/Phase 2
Completed NCT03372720 - Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors N/A
Recruiting NCT06413992 - Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer Phase 2
Recruiting NCT05316467 - Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma Phase 2/Phase 3